Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2018 (2018), Article ID 7685371, 13 pages
https://doi.org/10.1155/2018/7685371
Research Article

Frequency of Interferon-Resistance Conferring Substitutions in Amino Acid Positions 70 and 91 of Core Protein of the Russian HCV 1b Isolates Analyzed in the T-Cell Epitopic Context

1Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow 108819, Russia
2Russian Medical Academy of Continuous Professional Education, Moscow 125993, Russia
3Mechnikov Research Institute for Vaccines and Sera, Moscow 105064, Russia
4NF Gamaleja Research Center of Epidemiology and Microbiology, Moscow 123098, Russia
5Riga Stradins University, Riga LV-1007, Latvia

Correspondence should be addressed to V. S. Kichatova and K. K. Kyuregyan

Received 29 August 2017; Accepted 29 November 2017; Published 7 February 2018

Academic Editor: Pedro A. Reche

Copyright © 2018 V. S. Kichatova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. J. Liang, B. Rehermann, L. B. Seeff, and J. H. Hoofnagle, “Pathogenesis, natural history, treatment, and prevention of hepatitis C,” Annals of Internal Medicine, vol. 132, no. 4, pp. 296–305, 2000. View at Publisher · View at Google Scholar
  2. C. W. Shepard, L. Finelli, and M. J. Alter, “Global epidemiology of hepatitis C virus infection,” The Lancet Infectious Diseases, vol. 5, no. 9, pp. 558–567, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Thompson Coon, G. Rogers, P. Hewson et al., “Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis,” Health Technology Assessment, vol. 11, no. 34, pp. 1–206, 2007. View at Publisher · View at Google Scholar
  4. A. Petruzziello, S. Marigliano, G. Loquercio, A. Cozzolino, and C. Cacciapuoti, “Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes,” World Journal of Gastroenterology, vol. 22, no. 34, pp. 7824–7840, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. International Agency for Research on Cancer, World Cancer Report 2014, World Health Organization, Geneva, 2014.
  6. G. L. Armstrong, A. Wasley, E. P. Simard, G. M. McQuillan, W. L. Kuhnert, and M. J. Alter, “The prevalence of hepatitis C virus infection in the United States, 1999 through 2002,” Annals of Internal Medicine, vol. 144, no. 10, pp. 705–714, 2006. View at Publisher · View at Google Scholar
  7. P. Amoroso, M. Rapicetta, M. E. Tosti et al., “Correlation between virus genotype and chronicity rate in acute hepatitis C,” Journal of Hepatology, vol. 28, no. 6, pp. 939–944, 1998, 9672167. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Bréchot, “Hepatitis C virus: molecular biology and genetic variability,” Digestive Diseases and Sciences, vol. 41, Supplement 12, pp. 6S–21S, 1996. View at Publisher · View at Google Scholar
  9. T. Poynard, P. Bedossa, P. Opolon, and The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups, “Natural history of liver fibrosis progression in patients with chronic hepatitis C,” The Lancet, vol. 349, no. 9055, pp. 825–832, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Le Guen, G. Squadrito, B. Nalpas, P. Berthelot, S. Pol, and C. Brechot, “Hepatitis C virus genome complexity correlates with response to interferon therapy: a study in French patients with chronic hepatitis C,” Hepatology, vol. 25, no. 5, pp. 1250–1254, 1997. View at Publisher · View at Google Scholar
  11. J. B. Nousbaum, S. Pol, B. Nalpas et al., “Hepatitis C virus type 1b (II) infection in France and Italy,” Annals of Internal Medicine, vol. 122, no. 3, pp. 161–168, 1995. View at Publisher · View at Google Scholar
  12. S. Raimondi, S. Bruno, M. U. Mondelli, and P. Maisonneuve, “Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis,” Journal of Hepatology, vol. 50, no. 6, pp. 1142–1154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. W. Fried, M. L. Shiffman, K. R. Reddy et al., “Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” The New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. S. J. Hadziyannis, H. Sette Jr., T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–355, 2004. View at Publisher · View at Google Scholar
  15. M. P. Manns, J. G. McHutchison, S. C. Gordon et al., “Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” The Lancet, vol. 358, no. 9286, pp. 958–965, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Andriulli, F. Morisco, A. M. Ippolito et al., “HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome,” Hepatology International, vol. 9, no. 1, pp. 52–57, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. R. H. Westbrook and G. Dusheiko, “Natural history of hepatitis C,” Journal of Hepatology, vol. 61, no. 1, pp. S58–S68, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Akuta, F. Suzuki, H. Sezaki et al., “Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy,” Intervirology, vol. 48, no. 6, pp. 372–380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. El-Shamy and H. Hotta, “Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview,” World Journal of Gastroenterology, vol. 20, no. 24, pp. 7555–7569, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Akuta, F. Suzuki, M. Hirakawa et al., “Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin,” Hepatology, vol. 52, no. 2, pp. 421–429, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. N. Akuta, F. Suzuki, Y. Seko et al., “Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1,” Journal of Medical Virology, vol. 84, no. 7, pp. 1097–1105, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Akuta, F. Suzuki, Y. Kawamura et al., “Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis,” Hepatology, vol. 46, no. 5, pp. 1357–1364, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Okanoue, Y. Itoh, H. Hashimoto et al., “Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study,” Journal of Gastroenterology, vol. 44, no. 9, pp. 952–963, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. C. Jaspe, Y. F. Sulbarán, M. Z. Sulbarán, C. L. Loureiro, H. R. Rangel, and F. H. Pujol, “Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates,” Virology Journal, vol. 9, no. 1, p. 214, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Sultana, G. Oprişan, M. D. Teleman et al., “Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C,” World Journal of Gastroenterology, vol. 22, no. 37, pp. 8406–8413, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Alestig, B. Arnholm, A. Eilard et al., “Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection,” BMC Infectious Diseases, vol. 11, no. 1, article 124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. M. J. Donlin, N. A. Cannon, E. Yao et al., “Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy,” Journal of Virology, vol. 81, no. 15, pp. 8211–8224, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. F. A. Di Lello, J. A. Mira, K. Neukam et al., “Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection,” Archives of Virology, vol. 159, no. 12, pp. 3345–3351, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. F. S. Alhamlan, M. N. Al-Ahdal, N. Z. Khalaf et al., “Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy,” Journal of Medical Virology, vol. 86, no. 2, pp. 224–234, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Tasaka-Fujita, N. Sugiyama, W. Kang et al., “Amino acid polymorphisms in hepatitis C virus core affect infectious virus production and major histocompatibility complex class I molecule expression,” Scientific Reports, vol. 5, article 13994, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. El-Shamy, M. Pendleton, F. J. Eng, E. H. Doyle, A. Bashir, and A. D. Branch, “Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients,” Scientific Reports, vol. 6, article 27025, 2016. View at Publisher · View at Google Scholar · View at Scopus
  32. N. Akuta, F. Suzuki, Y. Seko et al., “Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis,” Hepatology, vol. 56, no. 6, pp. 2134–2141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Nakamoto, F. Imazeki, K. Fukai et al., “Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development,” Journal of Hepatology, vol. 52, no. 1, pp. 72–78, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Akuta, F. Suzuki, M. Hirakawa et al., “Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy,” Journal of Medical Virology, vol. 83, no. 6, pp. 1016–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Seko, N. Akuta, F. Suzuki et al., “Amino acid substitutions in the hepatitis C virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy,” Intervirology, vol. 56, no. 1, pp. 13–21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. A. El-Shamy, M. Shindo, I. Shoji, L. Deng, T. Okuno, and H. Hotta, “Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma,” Hepatology, vol. 58, no. 2, pp. 555–563, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Akuta, F. Suzuki, M. Kobayashi et al., “Impact of mutations at amino acid 70 in hepatitis C virus (HCV) genotype 1b core region on hepatocarcinogenesis following eradication of HCV RNA,” Journal of Clinical Microbiology, vol. 53, no. 9, pp. 3039–3041, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Kobayashi, T. Takeda, M. Enomoto et al., “Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients,” Liver International, vol. 27, no. 2, pp. 186–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Bailey, A. Turkova, and C. Thorne, “Syphilis, hepatitis C and HIV in Eastern Europe,” Current Opinion in Infectious Diseases, vol. 30, no. 1, pp. 93–100, 2017. View at Publisher · View at Google Scholar · View at Scopus
  40. A. V. Shustov, G. V. Kochneva, G. F. Sivolobova et al., “Molecular epidemiology of the hepatitis C virus in Western Siberia,” Journal of Medical Virology, vol. 77, no. 3, pp. 382–389, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. S. N. Kuzin, E. I. Samokhvalov, E. E. Zabotina et al., “Hepatitis virus genotype structure in patients with chronic hepatitis C,” Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii, no. 3, pp. 33–38, 2011. View at Google Scholar
  42. V. Kartashev, M. Döring, L. Nieto et al., “New findings in HCV genotype distribution in selected West European, Russian and Israeli regions,” Journal of Clinical Virology, vol. 81, pp. 82–89, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. A. J. Drummond and A. Rambaut, “BEAST: Bayesian evolutionary analysis by sampling trees,” BMC Evolutionary Biology, vol. 7, no. 1, p. 214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. R. Vita, J. A. Overton, J. A. Greenbaum et al., “The immune epitope database (IEDB) 3.0,” Nucleic Acids Research, vol. 43, no. D1, pp. D405–D412, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Molero-Abraham, E. M. Lafuente, D. R. Flower, and P. A. Reche, “Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses,” Clinical and Developmental Immunology, vol. 2013, Article ID 601943, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Lebedeva, A. Chumak, T. Pukhlikova, S. Pavlenko, V. Zinkin, and O. Mayorova, “The features of histocompatibility antigens polymorphism of cord blood samples in Moscow Blood Bank,” Bulletin of Hematology, vol. 11, no. 2, pp. 20-21, 2015. View at Google Scholar
  47. F. F. González-Galarza, L. Y. C. Takeshita, E. J. M. Santos et al., “Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations,” Nucleic Acid Research, vol. 43, no. D1, pp. D784–D788, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Andreatta, E. Karosiene, M. Rasmussen, A. Stryhn, S. Buus, and M. Nielsen, “Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification,” Immunogenetics, vol. 67, no. 11-12, pp. 641–650, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. I. Hoof, B. Peters, J. Sidney et al., “NetMHCpan, a method for MHC class I binding prediction beyond humans,” Immunogenetics, vol. 61, no. 1, pp. 1–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Nielsen and M. Andreatta, “NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets,” Genome Medicine, vol. 8, p. 33, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. A. K. Akhmineeva, HLA Phenotype and Clinical Course of Chronic Viral Hepatitis, [Ph.D. thesis], Astrakhan State Medical Academy, Astrakhan, 2008.
  52. A. Utama, N. P. Tania, R. Dhenni et al., “Genotype diversity of hepatitis C virus (HCV) in HCV-associated liver disease patients in Indonesia,” Liver International, vol. 30, no. 8, pp. 1152–1160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. I. Brahim, S. Ezzikouri, E. M. Mtairag et al., “Amino acid substitutions in the hepatitis C virus core region of genotype 1b in Moroccan patients,” Infection, Genetics and Evolution, vol. 14, pp. 102–104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. S. C. Ray, L. Fanning, X. H. Wang, D. M. Netski, E. Kenny-Walsh, and D. L. Thomas, “Divergent and convergent evolution after a common-source outbreak of hepatitis C virus,” Journal of Experimental Medicine, vol. 201, no. 11, pp. 1753–1759, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. R. Aurora, M. J. Donlin, N. A. Cannon, and J. E. Tavis, “Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans,” The Journal of Clinical Investigation, vol. 119, no. 1, pp. 225–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. Z. Hu, Y. Liu, L. Qiu et al., “Kinetic response of wild and mutant core codon 70 strains of HCV genotype 1b to pegylated interferon-α and ribavirin therapy,” Virology Journal, vol. 12, no. 1, p. 220, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. K. R. Reddy, J. H. Hoofnagle, M. J. Tong et al., “Racial differences in responses to therapy with interferon in chronic hepatitis C,” Hepatology, vol. 30, no. 3, pp. 787–793, 1999. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Isaguliants and N. Ozeretskovskaya, “Host background factors contributing to hepatitis C virus clearance,” Current Pharmaceutical Biotechnology, vol. 4, no. 3, pp. 185–193, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Tanaka, N. Nishida, M. Sugiyama et al., “Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C,” Nature Genetics, vol. 41, no. 10, pp. 1105–1109, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Fabris, E. Falleti, A. Cussigh et al., “IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC,” Journal of Hepatology, vol. 54, no. 4, pp. 716–722, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. Funaoka, N. Sakamoto, G. Suda et al., “Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91,” Journal of Virology, vol. 85, no. 12, pp. 5986–5994, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. N. Akuta, F. Suzuki, M. Hirakawa et al., “Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus,” Journal of Medical Virology, vol. 81, no. 6, pp. 1032–1039, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Uraki, M. Tameda, K. Sugimoto et al., “Substitution in amino acid 70 of hepatitis C virus core protein changes the adipokine profile via toll-like receptor 2/4 signaling,” PLoS One, vol. 10, no. 6, article e0131346, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Tachi, Y. Katano, T. Honda et al., “Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C,” Liver International, vol. 30, no. 4, pp. 554–559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. Y. Sumida, K. Kanemasa, T. Hara et al., “Impact of amino acid substitutions in hepatitis C virus genotype 1b core region on liver steatosis and glucose tolerance in non-cirrhotic patients without overt diabetes,” Journal of Gastroenterology and Hepatology, vol. 26, no. 5, pp. 836–842, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. A. V. Ivanov, V. T. Valuev-Elliston, D. A. Tyurina et al., “Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis,” Oncotarget, vol. 8, no. 3, pp. 3895–3932, 2017. View at Publisher · View at Google Scholar · View at Scopus
  67. M. J. Donlin, N. A. Cannon, R. Aurora et al., “Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients,” PLoS One, vol. 5, no. 2, article e9032, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. L. N. Cavalcante, K. Abe-Sandes, A. L. D. Angelo et al., “IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population,” Liver International, vol. 32, no. 3, pp. 476–486, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. U. Navaneethan, N. Kemmer, and G. W. Neff, “Review: predicting the probable outcome of treatment in HCV patients,” Therapeutic Advances in Gastroenterology, vol. 2, no. 5, pp. 287–302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. J. E. Layden-Almer, R. M. Ribeiro, T. Wiley, A. S. Perelson, and T. J. Layden, “Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin,” Hepatology, vol. 37, no. 6, pp. 1343–1350, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. J. H. Kao, S. H. Ahn, R. N. Chien et al., “Urgency to treat patients with chronic hepatitis C in Asia,” Journal of Gastroenterology and Hepatology, vol. 32, no. 5, pp. 966–974, 2017. View at Publisher · View at Google Scholar · View at Scopus
  72. N. Enomoto, I. Sakuma, Y. Asahina et al., “Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region,” The Journal of Clinical Investigation, vol. 96, no. 1, pp. 224–230, 1995. View at Publisher · View at Google Scholar
  73. M. Ragonnet-Cronin, S. Aris-Brosou, I. Joanisse et al., “Adaptive evolution of HIV at HLA epitopes is associated with ethnicity in Canada,” PLoS One, vol. 7, no. 5, article e36933, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Á. Patiño-Galindo and F. González-Candelas, “Comparative analysis of variation and selection in the HCV genome,” Infection, Genetics and Evolution, vol. 49, pp. 104–110, 2017. View at Publisher · View at Google Scholar · View at Scopus
  75. S. L. Rhodes, H. Erlich, K. A. Im et al., “Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection,” Genes & Immunity, vol. 9, no. 4, pp. 328–333, 2008. View at Publisher · View at Google Scholar · View at Scopus